Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03340766
Title Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)
Acronym HARBOUR
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | FRA | ESP | DEU | AUS


No variant requirements are available.